Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells
Song L, Ding S, Ge Z, Zhu X, Qiu C, Wang Y, Lai E, Yang W, Sun Y, Chow S, Yu L. Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells. British Journal Of Pharmacology 2017, 175: 1241-1259. PMID: 28910489, PMCID: PMC5866989, DOI: 10.1111/bph.14036.Peer-Reviewed Original ResearchConceptsReceptor tyrosine kinase internalizationExcessive ROS levelsConfocal immunofluorescence microscopyEndothelial cellsAntiretroviral therapyReceptor tyrosine kinasesMitochondrial DNA copy numberLymphatic endothelial cellsQuantitative real-time PCRMigration of ECsMitochondrial oxidative stressRTK endocytosisDNA copy numberProtein maturationRTK signalsEarly endosomesTube formation assaysTyrosine kinaseCardiovascular diseaseNucleoside/Blood vessel growthReal-time PCRFGFR1 pathwayCopy numberImmunofluorescence microscopy